Latest Earnings Results: Q2 '26
Estimated EPS
-$0.32
Reported EPS
-$0.31
Surprise
+4.37%
Estimated Rev
$254.99M
Reported Rev
$254.56M
Surprise
-0.17%
• Reported GAAP EPS of -$0.31 up 60.26% YoY • Reported revenue of $254.56M up 5.77% YoY
Bullish Takeaway
Tandem Diabetes Care delivered improved gross margins and increased global pump shipment volumes, while advancing its product pipeline through the recent FDA submission for Tandem Mobi tubeless capability.
Bearish Takeaway
Tandem Diabetes Care faces headwinds from ongoing supply chain inventory constraints, margin pressure from its new pharmacy channel business model, and intense competition in the insulin delivery technology market.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.24 | -- | -- | N/A |
Q2 '26 | -$0.32 | -$0.31 | 4.37% | BEAT |
Q1 '26 | -$0.44 | -$0.30 | 32.80% | BEAT |
Q4 '25 | -$0.09 | -$0.01 | 90.46% | BEAT |
Q3 '25 | -$0.33 | -$0.31 | 4.98% | BEAT |